HPV vaccine
US11638754B2 · kind B2 · utility
0Cited by
2References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2021 |
| Grant date | May 2, 2023 |
| Priority date | — |
| Expiry date | Feb 28, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/20071
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.